TD Cowen Mid‑Cap Stock Idea for 2026

TD Cowen released its best mid‑cap stock ideas for 2026, focusing on the healthcare sector and identifying companies with clear competitive advantages and sustainable growth trajectories. The firm highlighted BrightSpring Health Services Incorporated (ticker BTSG) as its top mid‑cap pick, a position the company also held in the 2025 selection.

Price Target and Valuation

TD Cowen raised its price target for BrightSpring to $81 per share, up from the previous target of $65. This represents a potential upside of 27% from the market price of $64.43 recorded on June 17, 2026. The rating assigned to the stock is Buy. The $81 target is derived from a five‑year discounted cash‑flow analysis and implies a valuation multiple of approximately 19‑20 times the company’s projected 2027 adjusted EBITDA of $998 million.

Growth Expectations

The analyst team expects BrightSpring to exceed its adjusted EBITDA growth target of 15‑20% through 2028, driven by exposure to high‑growth markets such as oncology, specialty pharmaceuticals, and infusion services. Key growth drivers identified include:

  • Wins in limited‑distribution drug (LDD) contracts;
  • Introduction of specialty oncology generics, specifically Pomalyst in 2026 and Ibrance and Xtandi in 2027;
  • Recovery and expansion of the infusion services business.

Market Position and Capital Structure

BrightSpring recently surpassed a $10 billion market‑capitalization threshold and has significantly reduced its leverage over the past year, factors that could attract additional institutional investor interest.

Peer Analyst Commentary

Goldman Sachs initiated coverage of BrightSpring with a Buy rating and a $71 price target, noting accelerating business momentum.

Secondary Offering Details

Certain shareholders priced a secondary offering of 15 million shares of common stock at $58.75 per share. BrightSpring did not receive any proceeds from this transaction.

Risks

TD Cowen flags several risks to the investment thesis: intense competition in the specialty pharmacy market from large pharmacy‑benefit managers operating affiliated specialty pharmacies, potential selling pressure stemming from KKR’s 22% ownership stake, and exposure of the provider business to Centers for Medicare & Medicaid Services (CMS) rate decisions.